دانا اليوم مستانسه

[al7bebe]

After Hours: 83.70 0.00 (0.00%)

Last Trade: 83.70
Trade Time: 4:00PM ET
Change: 1.30 (1.58%)
Prev Close: 82.40
Open: 81.40
Bid: N/A
Ask: N/A
1y Target Est: 94.70

Day's Range: 81.34 - 84.35
52wk Range: 75.58 - 100.20
Volume: 3,948,400
Avg Vol (3m): 3,113,000
Market Cap: 88.13B
P/E (ttm): 54.74
EPS (ttm): 1.53
Div & Yield: N/A (N/A)

http://finance.yahoo.com/q/bc?s=DNA&t=1y&l=on&z=m&q=c&c=

 

[al7bebe]

85.99 الهاي اليوم

الاست 85.91
الاغلاق السابق 83.20
بالتوفيق للجميع

 

[al7bebe]

86.28 الاغلاق

للمتابعه باكر .........

 

[smart_hasan]

انتبه فإعلان أرباحه غداً بعد إغلاق السوق ،،

الله يرزقك

 

[al7bebe]

مشكورين على التنبيه

انتبه فإعلان أرباحه غداً بعد إغلاق السوق ،،

الله يرزقك

.
وكثر الله من امثالكم الطيبين في كل مكان وزمان

 

[FreeTrader]

DNA Genentech beats by $0.08, beats on revs; raises Y06 EPS guidance (85.91 -0.37)

Reports Q3 (Sep) earnings of $0.55 per share, including $0.04 option expense & excluding non-recurring items, $0.08 better than the Reuters Estimates consensus of $0.47; reports earnings of $0.59, excluding option expense & items, vs. $0.51 First Call consensus; revenues rose 36.1% year/year to $2.38 bln vs the $2.32 bln consensus. Co expects non-GAAP EPS growth of 65-70% which equates to $2.11-2.18 vs. 2.05 First Call consensus, up from previous guidance of 55-60%, comparable to $1.98-2.05. Co reports Rituxan Q3 sales of $509.00 mln vs. $547.5 mln street expectation; reports Avastin Q3 sales of $435 mln vs. $471.5 mln street expectation; reports Avastin Q3 sales of $435 mln vs. $471.5 mln street expectation; reports Avastin Q3 sales of $435 mln vs. $471.5 mln street expectation; reports Xolair Q3 sales of $107 mln vs. $110.2 mln street expectation; reports Raptiva Q3 sales of $23 mln vs. $24.9 mln street expectation; reports Lucentis Q3 sales of $153 mln.